Bower D J
University of Aberdeen.
J Manag Med. 1994;8(4):54-61. doi: 10.1108/02689239410068561.
Essential parts of the R&D in virtually all UK biomedical innovations are executed within teaching hospitals, which are undergoing major organizational changes as part of the ongoing NHS reforms. Examines the impact of the changing structural and regulatory environment on the process of biomedical innovation management of two groups of technologically novel projects with the NHS. Finds that regulatory changes were tending to centralize and formalize innovation management, but that end users were playing an active role in directing the course of new treatment development. Problems of allocation of R&D resources within teaching hospitals were still unresolved, although some evidence from the London teaching hospitals suggested that hospital managers were able to deal with conflicting demands where they perceived that research excellence could be an asset rather than a cost.
几乎所有英国生物医学创新研发的关键部分都在教学医院内进行，而作为国民保健制度（NHS）持续改革的一部分，这些教学医院正在经历重大的组织变革。研究了不断变化的结构和监管环境对国民保健制度两组技术新颖项目的生物医学创新管理过程的影响。发现监管变化倾向于使创新管理集中化和形式化，但终端用户在指导新治疗方法的开发过程中发挥着积极作用。教学医院内部研发资源的分配问题仍未得到解决，尽管来自伦敦教学医院的一些证据表明，医院管理者在他们认为卓越的研究可能是一种资产而非成本的情况下，能够应对相互冲突的需求。
